Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme
- PMID: 25771905
- PMCID: PMC4480943
- DOI: 10.1007/s00259-015-3022-9
Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme
Abstract
Purpose: Health-related quality of life (HRQOL) in differentiated thyroid cancer (DTC) research has so far received little attention and available results are conflicting. We studied the HRQOL of radioiodine-naive DTC patients in comparison with the general population (GP), investigated the course of HRQOL up to 30 months after radioiodine remnant ablation (RAA) and sought to identify patient characteristics associated with HRQOL.
Methods: We analysed data from routine HRQOL monitoring at a nuclear medicine department. Between 2005 and 2013, a total of 439 thyroid cancer patients (all histologies) completed the EORTC Quality of Life Questionnaire Core-30 (QLQ-C30) at least once during their treatment at the department. We compared patients' baseline HRQOL scores before RAA with scores from age-matched and sex-matched controls from the Austrian GP. We then determined the course of HRQOL over the 30 months after RAA and assessed the impact of the following clinical variables on HRQOL: method of thyroid-stimulating hormone (TSH) stimulation, histology (papillary vs. follicular) and disease stage.
Results: A total of 284 patients (mean age 48.3 years, SD 15.0 years; 71.6% women; 80.7% papillary type) with a baseline HRQOL assessment before RAA were available. We found clinically meaningful differences in the detriment in patients on almost all domains. These were largest for fatigue (23 points) and role functioning (25 points). Data from 241 patients (mean age 48.6 years, SD 15.9 years; 68.9% women; 76.3% papillary type) were included in the longitudinal analysis. Investigating the course of HRQOL, a significant improvement over time was found for role and emotional functioning, fatigue, pain, and dyspnoea. A range of HRQOL scores were improved in patients with exogenous TSH stimulation, but some scores both in patients with exogenous TSH stimulation and in those followed for 30 months, especially fatigue and role functioning, did not reach levels in the GP sample.
Conclusion: Our results show that the favourable prognosis of DTC does not directly translate into good HRQOL in these patients. Persistent restrictions in regaining their normal daily life in terms of work and leisure highlight the importance of more detailed investigation of DTC patients' wellbeing, support needs, and disease experience.
Figures
Similar articles
-
Five-Year Follow-Up of Health-Related Quality of Life in Differentiated Thyroid Cancer Patients Treated with Total Thyroidectomy and Radioiodine in Sweden: A Nationwide Prospective Cohort Study.Thyroid. 2024 Jun;34(6):713-722. doi: 10.1089/thy.2023.0691. Epub 2024 Apr 5. Thyroid. 2024. PMID: 38526369
-
Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.Lancet Oncol. 2009 Dec;10(12):1160-70. doi: 10.1016/S1470-2045(09)70258-X. Epub 2009 Oct 12. Lancet Oncol. 2009. PMID: 19828373 Clinical Trial.
-
Health status of Greek thyroid cancer patients after radioiodine administration compared to a demographically matched general population sample.Hell J Nucl Med. 2012 May-Aug;15(2):98-102. doi: 10.1967/s002449910028. Epub 2012 Jun 27. Hell J Nucl Med. 2012. PMID: 22741146
-
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.Endocr Relat Cancer. 2005 Mar;12(1):49-64. doi: 10.1677/erc.1.00830. Endocr Relat Cancer. 2005. PMID: 15788638 Review.
-
Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.Endocr Relat Cancer. 2005 Dec;12(4):773-803. doi: 10.1677/erc.1.00880. Endocr Relat Cancer. 2005. PMID: 16322322 Review.
Cited by
-
Evaluation of Quality of Life in Patients with Differentiated Thyroid Cancer by Means of the Thyroid-Specific Patient-Reported Outcome Questionnaire: A 5-Year Longitudinal Study.Eur Thyroid J. 2020 Sep;9(5):247-255. doi: 10.1159/000501201. Epub 2019 Jul 24. Eur Thyroid J. 2020. PMID: 33088793 Free PMC article.
-
Papillary Thyroid Cancer: The Good and Bad of the "Good Cancer".Thyroid. 2017 Jul;27(7):902-907. doi: 10.1089/thy.2016.0632. Epub 2017 Jun 12. Thyroid. 2017. PMID: 28510505 Free PMC article.
-
The impact of electronic versus paper-based data capture on data collection logistics and on missing scores in thyroid cancer patients.Endocrine. 2024 May;84(2):635-645. doi: 10.1007/s12020-023-03628-9. Epub 2023 Dec 16. Endocrine. 2024. PMID: 38103143 Free PMC article.
-
Risk Factors of Deterioration in Quality of Life Scores in Thyroid Cancer Patients After Thyroidectomy.Cancer Manag Res. 2019 Dec 19;11:10593-10598. doi: 10.2147/CMAR.S235323. eCollection 2019. Cancer Manag Res. 2019. PMID: 31908531 Free PMC article.
-
Patient Experience of Thyroid Cancer Active Surveillance in Japan.JAMA Otolaryngol Head Neck Surg. 2019 Apr 1;145(4):363-370. doi: 10.1001/jamaoto.2018.4131. JAMA Otolaryngol Head Neck Surg. 2019. PMID: 30703198 Free PMC article.
References
-
- Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006;91(3):878–884. doi: 10.1210/jc.2005-2064. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical